PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

LinkedIn

Ethanol as a Context-Dependent Modifier of Drug Toxicity

ethanolalcoholdrug interactionsCYP2E1CYP3Acarboxylesterase 1disulfiramdose dumpingwarfarinmetforminSGLT2 inhibitorsacetaminophenNSAIDsopioidsbenzodiazepinesalcohol-associated liver diseasenarrative reviewpharmacokineticspharmacodynamics Geriatrics / Geriatric Pharmacy

Background Information

Ethanol dramatically alters drug toxicity, posing high risks for older adults.

Ethanol can significantly alter drug response and toxicity, which is particularly crucial for older adults who may have reduced organ reserve and are often on multiple medications. Ethanol affects drug pharmacokinetics and pharmacodynamics through mechanisms like CYP2E1 induction, acetaldehyde accumulation, and disrupted protein binding, especially in older adults and those with liver disease. Understanding these interactions is essential for managing medications in older adults, particularly those with alcohol use disorder or liver disease, to prevent adverse drug events. Ethanol is a potent modifier of drug toxicity, especially in older adults with complex health conditions.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribe for Full Access →

Authors: Bukowska B, Bukowski K, Broncel M

Citation: Bukowska B, Bukowski K, Broncel M Ethanol as a Modifier of Drug Toxicity in Humans: Pathways of Toxicity and Organ-Level Consequences. International journal of molecular sciences. 2026;27(14). doi:10.3390/ijms27146270

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →